Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01619332
Other study ID # CLEZ763X2201
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2012
Est. completion date September 2013

Study information

Verified date March 2016
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion criteria: - All subjects: (suggest this will reduce duplication) - Male or female aged 18-65 yr, - Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI) must be within the range of 18-37 kg/m2 (inclusive - Only postmenopausal females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study. - Subjects with stable conventional sleep-wake cycle Normal Healthy Volunteers - Healthy male or female subjects, - must be in good health (as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening). Type II Diabetic Patients - Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening. - Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study. - HbA1c 6.5 to 9.5 % inclusive at screening Exclusion criteria: All subjects: - Smokers (use of tobacco products in the previous 3 months). - Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation. - Significant illness within two weeks prior to dosing. - Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations Normal Healthy Volunteers • History of diabetes, or adrenal disorders. Type II Diabetic Patients - Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes - Evidence of clinically significant diabetic complications (such nephropathy, retinopathy, neuropathy) Other protocol defined inclusion/exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
Sitagliptin
Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
LEZ763
LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

Locations

Country Name City State
United States Novartis Investigative Site Chula Vista California
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Knoxville Tennessee
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Orlando Florida
United States Novartis Investigative Site San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients with adverse events, serious adverse events and death An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations. Day 28
Primary Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4
Primary Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10
Primary Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10
Primary Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Primary Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Primary Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Primary Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Primary Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27
Primary Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Primary Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Primary Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax) Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28
Primary Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test 4 hour post-dose Day 27
Secondary Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours) GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28
Secondary 2-hour value of post-prandial glucose Day 1 of Part I, Day 1 and day 10 of Part II
Secondary Change from baseline in Fasting C-peptide at Day 27 (Part III) Baseline, Day 27
Secondary Change from baseline in Fasting Insulin at Day 27 (Part III) Baseline , Day 27
Secondary Change from baseline in fasting plasma glucose at Day 27 (Part III) Baseline , Day 27
Secondary Change From Baseline in peak glucose level following meal Test at Day 27 (Part III) Baseline , Day 27
Secondary Peak effect (Emax) on postprandial GLP-1 (Part III) Baseline , Day 27
Secondary Change from baseline in Peptide YY (PYY) (Part III) Baseline , Day 27
Secondary Change from baseine in Gastric inhibit polypeptide (GIP) (Part III) Baseline , Day 27
See also
  Status Clinical Trial Phase
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Withdrawn NCT04569214 - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients Phase 2
Completed NCT01698528 - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration N/A
Completed NCT00985114 - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity N/A
Active, not recruiting NCT05120219 - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers Phase 1
Completed NCT04893135 - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes N/A
Not yet recruiting NCT05108350 - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects Phase 1
Completed NCT02586129 - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes Phase 3
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT04540016 - Mass Balance and Biotransformation of [14C]HSK7653 in Human Phase 1
Completed NCT02429258 - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin Phase 4
Completed NCT01055223 - Fracture Risk With Thiazolidinediones N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Completed NCT05878587 - Burger Allen Exercises in Knee OA With Type II Diabetes N/A
Completed NCT04768673 - A Study to Investigate the PK and Safety of CKD-393 Phase 1
Not yet recruiting NCT05028140 - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Phase 3
Terminated NCT01804777 - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes Early Phase 1
Active, not recruiting NCT06387433 - Effectiveness of an mHealth Mobile App N/A
Not yet recruiting NCT01591525 - Diabetes Mellitus Community Based Screening in Minority Populations N/A
Completed NCT01881074 - Periodontal Treatment Response in Type II Diabetic Patients